A survey of exposure to the use of Xiaflex for the treatment of Peyronie’s disease among United States urology residency programs

Xiaflex® (collagenase clostridium histolyticum) is a Food and Drug Administration-approved treatment for patients with Peyronie’s disease. Despite its approval and implementation, there is concern that urologists in training are offered minimal exposure to its use. Thus, the purpose of this study was to evaluate the exposure of urology residents to Peyronie’s disease and its management, particularly Xiaflex®. A Google Forms survey regarding the exposure of residents to Peyronie’s disease and use of Xiaflex® was created and disseminated through email to urology programs. Overall, 47 institutional responses were received. At 45 institutions (95.7%), residents receive training in directly evaluating and caring for patients with Peyronie’s disease. At 46 institutions (97.9%), residents receive training in observing and/or performing surgical procedures for Peyronie’s disease. Residents at 31 institutions (66.0%) receive observational or procedural training for non-surgical management of Peyronie’s disease, specifically Xiaflex®. Residents receive non-surgical training from an academic faculty who is fellowship trained in sexual medicine at 25 institutions and an academic faculty not trained in sexual medicine at six institutions. There exists a glaring disparity in residency exposure to Xiaflex®. Further research is warranted to elucidate how programs can provide residents with further exposure to the use of Xiaflex® in patients with Peyronie’s disease.